# **Special Issue**

## **Next Generation of MRI Agents**

## Message from the Guest Editors

Contrast agents have served an essential role in the development and clinical translation of magnetic resonance imaging (MRI) during the last 40 years. The first agents developed in the 1980s were designed to change the MR image contrast to identify anatomical features, such as solid tumors that had enhanced the uptake of nonspecific tracers. These agents are still commonly used for qualitative assessments of many clinical pathologies. These nonspecific tracer agents began to be temporally monitored in the 1990s as an agent was intravenously injected, then flowed through the vasculature and eventually permeated into the tissue of interest, such as a kidney or tumor. Semiguantitative and quantitative evaluations of the pharmacokinetics of these agents provided functional information, especially for studies in cardiology and oncology.

## **Guest Editors**

Prof. Dr. Andre F. Martins

- Werner Siemens Imaging Center, Department of Preclinical Imaging and Radiopharmacy, Eberhard Karls University Tübingen, 72076 Tübingen, Germany
- 2. Cluster of Excellence iFIT (EXC 2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tuebingen, 72076 Tübingen, Germany
- 3. German Cancer Consortium, DKFZ Partner Site Tübingen, 72076 Tübingen, Germany

Dr. Mark Pagel

MD Anderson Cancer Center, University of Texas, Houston, TX, USA

## Deadline for manuscript submissions

closed (31 December 2020)



## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/43057

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





## **Pharmaceuticals**

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



## **About the Journal**

## Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

#### Editor-in-Chief

#### Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

### **Author Benefits**

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

## **High Visibility:**

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

